Precursor Cell Lymphoblastic Leukemia-Lymphoma: Clinical Trials

1345 completed, 354 recruiting, 316 terminated, 316 unknown. 983 Phase 2, 917 Phase 1, 372 Not applicable, 212 Phase 3, 62 Phase 4.

By phase and status

Phase	Trials	Status
Phase 2	983	Completed 473, Terminated 146, Recruiting 136, Unknown 93, Active not recruiting 71, Withdrawn 38, Not yet recruiting 17, Suspended 6, Enrolling by invitation 3
Phase 1	917	Completed 458, Terminated 141, Recruiting 112, Unknown 79, Active not recruiting 58, Withdrawn 45, Not yet recruiting 14, Suspended 9, Enrolling by invitation 1
Not applicable	372	Completed 186, Recruiting 63, Unknown 38, Terminated 31, Not yet recruiting 24, Withdrawn 13, Active not recruiting 12, Enrolling by invitation 3, Suspended 2
Phase 3	212	Completed 113, Unknown 31, Recruiting 22, Terminated 18, Active not recruiting 17, Withdrawn 6, Not yet recruiting 4, Suspended 1
Phase 4	62	Completed 30, Unknown 18, Terminated 6, Recruiting 5, Active not recruiting 1, Enrolling by invitation 1, Withdrawn 1
Early Phase 1	42	Completed 11, Recruiting 11, Unknown 7, Terminated 5, Not yet recruiting 4, Active not recruiting 3, Withdrawn 1

Follow Precursor Cell Lymphoblastic Leukemia-Lymphoma: new trials by email Literature Review of Precursor Cell Lymphoblastic Leukemia-Lymphoma trials Research Report on Precursor Cell Lymphoblastic Leukemia-Lymphoma

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Lymphoblastic Leukaemia Blinatumomab, HyperCVAD - Philadelphia Chromosome Negative B-cell Precursor Acute Lymphoblastic Leukemia	Phase 3	Not yet recruiting	Amgen	560	2028-06-30	2026-09-15
Pyronaridine in Acute Myeloid Leukemia (AML) Pyronaridine Tetraphosphate - Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL)	Phase 2	Suspended	Armaceutica, Inc.	200	2028-02-21	2026-10-19
VR-PAT and fNIRS to Identify CNS Biomarkers of Pain VR-PAT - Acute Pain, Pediatric ALL	Not applicable	Not yet recruiting	Nationwide Children's Hospital	4	2027-07-01	2026-09-09
Universal 4SCAR7U Targeting CD7-positive Malignancies Universal CD7-specific CAR gene-engineered T cells - T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma	Phase 1	Not yet recruiting	Shenzhen Geno-Immune Medical Institute	30	2027-06-30	2026-11-02
Genetically Engineered Cells (BAFFR-CAR T Cells) for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Lymphoblastic Lymphoma Autologous BAFFR-targeting CAR T Cells, Biospecimen Collection, Bone Marrow Aspiration - Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma	Phase 1	Not yet recruiting	City of Hope Medical Center	16	2027-04-17	2026-08-11
Phase I Safety Clinical Trial of Anti-CD19 CAR-T Therapy COL01 for the Treatment of Adults With Relapsed or Refractory B-cell Lymphoid Neoplasms: First-in-human Administration, COLIBRI. CAR-T anti-CD19 COL01 - Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia, Lymphoid Malignancies	Phase 1	Not yet recruiting	GUSTAVO SALGUERO	12	2027-04-01	2026-10-20
2 Gy Total Body Irradiation As Part Of Conditioning Treatment For Patients With Acute Lymphoblastic Leukemia Undergoing CAR T Cell Therapy CAR T cell therapy - Acute Lymphoblastic Leukemia	Not applicable	Not yet recruiting	M.D. Anderson Cancer Center	20	2027-03-01	2026-10-05
Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration Non-Interventional Study - Childhood Acute Lymphoblastic Leukemia, Childhood Lymphoblastic Lymphoma		Not yet recruiting	Mayo Clinic	20	2027-02-01	2026-04-02
Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL) Blinatumomab, olverembatinib - Phase II Clinical Trial, Blinatumomab	Phase 2	Not yet recruiting	M.D. Anderson Cancer Center	60	2027-01-27	2026-10-07
Subcutaneous Blinatumomab Plus Ponatinib for BCR-ABL+ B-ALL Treatment with blinatumomab given subcutaneously. - Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+), BCR-ABL Positive Acute Lymphoblastic Leukemia	Phase 2	Not yet recruiting	University of Alberta	80	2027-01-02	2026-08-12
CD34+ Transplants for Myeloid Malignancies Busulfan, Melphalan, Fludarabine - Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute	Phase 2	Not yet recruiting	Guenther Koehne	50	2027-01-01	2026-10-13
Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome Allogeneic CD34+-enriched and CD45RA-depleted PBSCs, Biospecimen Collection, Bone Marrow Aspiration - Acute Biphenotypic Leukemia, Acute Leukemia	Phase 2	Not yet recruiting	Fred Hutchinson Cancer Center	52	2027-01-01	2026-09-14
Prevention of Oral Mucositis in Adults in With Hematologic Malignancy Aloe Vera Mouthwash, Standard of Care - Acute Leukemia, Acute Myeloid Leukemia	Not applicable	Not yet recruiting	Wake Forest University Health Sciences	206	2027-01-01	2026-10-22
huCART19-IL18-CD428z Cells for the Treatment of Patients With HIV With CD19+ Cancers huCART19-IL18-CD428z cells - Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia	Phase 1	Not yet recruiting	University of Pennsylvania	6	2027-01-01	2026-11-02
Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies CD7-specific CAR gene-engineered T cells - T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma	Phase 1 / Phase 2	Not yet recruiting	Shenzhen Geno-Immune Medical Institute	30	2026-12-31	2026-11-02
A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia sonrotoclax, Azacitidine, Inotuzumab ozogamicin - Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia	Phase 1 / Phase 2	Not yet recruiting	BeOne Medicines	30	2026-12-01	2026-10-26
Study to Characterize Mismatched to Fully HLA-Matched Ossium HPC, Marrow and Living Donor Transplantation in Patients With Hematologic Malignancies Ossium HPC, Marrow, Standard of care living donor - Haplo Related, Standard of care living donor - Mismatched Unrelated - Hematologic Malignancy, Acute Leukemia	Not applicable	Not yet recruiting	Ossium Health, Inc.	300	2026-12-01	2026-09-10
Digital Patient-Reported Assessment in Older Adults With Acute Leukemia Digital Patient-Reported Assessment Pathway - Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia	Not applicable	Not yet recruiting	Fundación para la Investigación Biosanitaria del Principado de Asturias	20	2026-12-01	2026-10-07
CD19 CAR-T Cell Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: A Phase I/II Study MB-CART19.1 - Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia	Phase 1 / Phase 2	Not yet recruiting	Hospital Universitario Dr. Jose E. Gonzalez	30	2026-12-01	2026-10-22
A Study of LP-118 In Combination With Ponatinib, Dexamethasone And Blinatumomab For Adults With Newly-Diagnosed, BCR::ABL1-Positive Acute Lymphoblastic Leukemia (ALL) LP-118 - Philadelphia Positive Acute Lymphoblastic Leukemia	Phase 1	Recruiting	Wake Forest University Health Sciences	26	2026-12-01	2026-10-29

Showing 20 of 2699. Sign in to see all of them.

Narrower conditions

Leukemia, Myeloid, Acute (864)  ·  Lymphoma, Non-Hodgkin (696)  ·  Leukemia (650)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (647)  ·  Burkitt Lymphoma (610)  ·  Lymphoma (542)  ·  Lymphoma, Large B-Cell, Diffuse (523)  ·  Myelodysplastic Syndromes (517)  ·  Lymphoma, Mantle-Cell (497)  ·  Lymphoma, Follicular (496)  ·  Hodgkin Disease (485)  ·  Lymphoma, B-Cell, Marginal Zone (437)  ·  Lymphoma, Large-Cell, Immunoblastic (430)  ·  Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (419)

Broader conditions

Hemic and Lymphatic Diseases (2699)  ·  Neoplasms by Histologic Type (2693)  ·  Immune System Diseases (2688)  ·  Immunoproliferative Disorders (2688)  ·  Lymphatic Diseases (2688)  ·  Hematologic Diseases (2681)  ·  Leukemia, Lymphoid (2672)  ·  Lymphoproliferative Disorders (2651)  ·  Neoplasms (2570)  ·  Leukemia (2049)  ·  Pathological Conditions, Signs and Symptoms (1205)  ·  Pathologic Processes (1153)  ·  Disease Attributes (1066)  ·  Leukemia, Myeloid (981)  ·  Chronic Disease (920)

Interventions

Cyclophosphamide (449)  ·  Methotrexate (269)  ·  Cytarabine (257)  ·  Vincristine (218)  ·  Dexamethasone (194)  ·  fludarabine phosphate (183)  ·  Etoposide (155)  ·  fludarabine (155)  ·  Peripheral Blood Stem Cell Transplantation (140)  ·  Filgrastim (137)  ·  Doxorubicin (134)  ·  Mercaptopurine (120)  ·  Whole-Body Irradiation (119)  ·  Mycophenolic Acid (118)  ·  Busulfan (116)

Sponsors

National Cancer Institute (NCI) (167)  ·  Fred Hutchinson Cancer Center (96)  ·  M.D. Anderson Cancer Center (95)  ·  Children's Oncology Group (75)  ·  St. Jude Children's Research Hospital (72)  ·  City of Hope Medical Center (55)  ·  Memorial Sloan Kettering Cancer Center (48)  ·  Masonic Cancer Center, University of Minnesota (45)  ·  Case Comprehensive Cancer Center (32)  ·  Novartis Pharmaceuticals (32)  ·  Institute of Hematology & Blood Diseases Hospital, China (28)  ·  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (28)  ·  Dana-Farber Cancer Institute (22)  ·  Gruppo Italiano Malattie EMatologiche dell'Adulto (22)  ·  Mayo Clinic (19)

Countries

United States (1617)  ·  China (247)  ·  Canada (179)  ·  France (155)  ·  Italy (152)  ·  Germany (134)  ·  Spain (104)  ·  United Kingdom (103)  ·  Australia (98)  ·  Netherlands (72)  ·  Denmark (68)  ·  Switzerland (61)  ·  Belgium (58)  ·  Israel (49)  ·  Russia (48)

Top investigators

Brenda Sandmaier (13)  ·  Elias Jabbour (9)  ·  Xiaofan Zhu, MD (8)  ·  Ajay Gopal (7)  ·  Kjeld Schmiegelow, M.D. (7)  ·  Sima Jeha, MD (7)  ·  David Maloney (6)  ·  Dieter Hoelzer, MD,PhD (6)  ·  Ibrahim Aldoss (6)

Results publications

PMID 41671463, PMID 35622074, PMID 32499241, PMID 34515338, PMID 23524640, PMID 33242441, PMID 23065508, PMID 34048072, PMID 39121442, PMID 27209293, PMID 22442346, PMID 28054442, PMID 35007144, PMID 35422096, PMID 37890117, PMID 38446568, PMID 40195173, PMID 41592282, PMID 15812540, PMID 19141862, PMID 19144982, PMID 19949018, PMID 20028764, PMID 21195303, PMID 21527516, PMID 21623761, PMID 21715313, PMID 21719599, PMID 21940824, PMID 22002018, PMID 22133778, PMID 22337718, PMID 22493293, PMID 22677206, PMID 23024237, PMID 24428625, PMID 24862638, PMID 24970932, PMID 25753432, PMID 26432046, PMID 26590194, PMID 26888258, PMID 27561722, PMID 27873237, PMID 28751559, PMID 29284596, PMID 29358182, PMID 29518185, PMID 29618479, PMID 30957229

NIH funding

P30CA015704 (42), P30CA033572 (39), U10CA098543 (30), P30CA043703 (24), P01CA018029 (19), P30CA006973 (19), U10CA180886 (16), U10CA032102 (15), P30CA015083 (14), U01CA070095 (12), U01CA097452 (12), P30CA016672 (11), P30CA022453 (11), P30CA072720 (11), P01CA078902 (10)